Two pharma giants are combining forces to take on multiple cancers in a deal worth up to $8.5 billion.
AstraZeneca’s combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, triggering the biggest ever daily fall in its shares.
Cochlear Ltd. said it can now stream audio directly from Apple Inc.’s iPhone, iPad and iPod to the microchips in its hearing implants without having to use an additional device.
HIV-positive patients may soon have a new treatment option that can be taken without food restrictions and has a much lower rate of drug interference with other medications patients may be taking.
A preliminary advisory committee report by the FDA once again pointed to some serious safety issues with Dynavax Technologies’ troubled hepatitis B treatment Heplisav-B.
GSK’s new chief executive announced plans to narrow the focus of the group’s drug research by ditching 30-plus projects to improve returns in its core pharma business.
Anthem Inc. said it may exit more individual Obamacare markets as the future of the national healthcare law and the government subsidies that make insurance affordable for millions of Americans remain up in the air.
After a months-long struggle, Republicans have succeeded in bringing Obamacare repeal legislation – a centerpiece of their 2016 election campaigns – to a debate on the U.S. Senate floor.
FDA’s commissioner told staff in an email that he intends to delay any labor reductions until the end of September unless Congress authorizes its user fee program to provide the necessary funding.
Razorfish Health Announces the Promotion of Keri Hettel to SVP, Analytics and Strategy and Brandon Ashcraft to SVP, Operations
Razorfish Health, a uniquely integrated health and wellness advertising agency, announced the promotion of Keri Hettel to SVP, Analytics and Strategy, and Brandon Ashcraft to SVP, Operations.
Klick Health’s Incubated Startup Circulation Announces New Strategic Alliances and Series A Financing Closing
The health marketing and commercialization agency continues focus on growing healthcare commercialization practice and introducing more innovative business models to industry.
Decreasing sensitivity to insulin — often associated with obesity and eventual type 2 diabetes — may also cause young adults to have lower bone mass at a time of life when it should be at its peak, Korean researchers say.
Takeda and BioSurfaces announced a deal to initiate a research program designed to develop innovative medical devices to treat patients with GI diseases.
Eli Lilly reported an increase of 8 percent in second-quarter 2017 revenue, but the real shake-up is what the company plans to do with its pipeline.
Biogen Inc.’s second-quarter 2017 profit smashed estimates, boosted by strong sales of the company’s spinal muscular atrophy (SMA) drug Spinraza, which is priced at $750,000 for the first year of therapy.
Japan-based Astellas Pharma is setting up a new facility in Cambridge, Mass. which is in line with the company’s 2016 strategic focus on innovation and enhancing its capabilities in developing dynamic new treatments to address unmet medical needs.
Merck’s vaunted PD-1 inhibitor Keytruda suffered another setback when it failed to meet endpoints in a Phase III head and neck cancer study.
A federal jury in Chicago found AbbVie Inc. fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 million in punitive damages.
Discovery Worldwide, a healthcare communications agency that combines the power of science, storytelling and innovative delivery to move health forward, announces the appointment of Rico Ricketson as Head of Client Services.
Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin
Pfizer Inc. today announced that the REFLECTIONS B7391003 study — a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin (bevacizumab) — met its primary objective. PF-06439535 is being developed by Pfizer as a potential biosimilar to Avastin.